| DOI | Resolve DOI: https://doi.org/10.1016/j.jalz.2012.05.1556 |
|---|
| Author | Search for: Badhwar, Aman; Search for: Brown, R.1; Search for: Delaney, Christie1; Search for: Stanimirovic, D.B.1; Search for: Haqqani, Arsalan1; Search for: Hamel, Edith |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
|---|
| Format | Text, Article |
|---|
| Subject | Alzheimer's disease; amyloid precursor protein mice; pioglitazone; cerebrovascular impairment |
|---|
| Abstract | Cerebrovascular dysfunction appears prior to Aβ-plaque deposition and measurable mnemonic impairment in Alzheimer's disease (AD) patients and amyloid precursor protein (APP)-expressing transgenic mice. The soluble, highly toxic Aβ-fragment generated from the amyloidogenic processing of APP is likely the primary instigator of chronic cerebrovascular insufficiency in APP mice. We recently demonstrated that the PPAR-gamma agonist, pioglitazone, is a potent drug for reversing cerebrovascular impairment at all stages of Aβ-induced pathology in APP mice. Our aims are to (a) characterize the effect of Aβ-overproduction on the cerebrovascular proteome of APP mice; (b) determine the extent to which pioglitazone rescues the Aβ-altered cerebrovascular proteome; and (c) determine the link between protein expression rescue by pioglitazone and functional recovery in the cerebrovasculature. |
|---|
| Publication date | 2012-07 |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| NPARC number | 21275162 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 50e79eaa-a6de-455b-bb31-5c57caea16f6 |
|---|
| Record created | 2015-05-21 |
|---|
| Record modified | 2020-04-21 |
|---|
